Clinical and public health implications of macrolide-resistant Streptococcus pneumoniae

Clinical and public health implications of macrolide-resistant Streptococcus pneumoniae

Moellering R C; Consensus Working Grp

Journal of Chemotherapy

2002

2002-07

Macrolide resistance among Streptococcus pneumoniae is a growing global concern, although its specific impact on public health is not currently well defined. A Consensus Working Group was convened in March 2001 to address whether credible, scientific data substantiate macrolide resistance in S. pneumoniae as: (i) producing significant morbidity; (ii) creating attendant health and economic burdens; (iii) constituting a public health threat; and (iv) warranting intervention, including development of new antibiotics with efficacy against these strains. Despite the limitations of available clinical data, concern about the possibility of treatment failure with macrolides is being expressed in clinical practice and in formal treatment guidelines, threatening the important role of these agents in the treatment of respiratory tract infections. Further studies are required to monitor and control macrolide resistance and evaluate settings in which macrolide treatment failures are occurring, and new therapeutic interventions are needed.

Infectious Diseases; Pathology; united-states; Pharmacology & Pharmacy; in-vitro; Oncology; community-acquired pneumonia; macrolide resistance; streptococci; respiratory; pneumoniae; haemophilus-influenzae; moraxella-catarrhalis; tract infections; macrolides; otitis-media; group-a; erythromycin resistance; decreased susceptibility; initial antimicrobial therapy; pneumococcal resistance; S.; treatment failure

Journal Article or Conference Abstract Publication

Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).

42-56

14